{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:57:52Z","timestamp":1773197872302,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104958","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:18:37Z","timestamp":1773123517000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Survival Achieved by Combined Surgical Resection and Immunotherapy for Recurrent Adrenal Oligometastasis of Lung Adenocarcinoma: A Case Study"],"prefix":"10.7759","author":[{"given":"Sachie","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kiwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Aida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Hizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West H","year":"2019","unstructured":"West H, McCleod M, Hussein M, et al.. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20:924-37. 10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski MA","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, et al.. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018, 378:2288-301. 10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-83","article-title":"Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study","volume":"12","author":"Wang Q","year":"2023","unstructured":"Wang Q, Fang Y, Li C, et al.. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study. Transl Lung Cancer Res. 2023, 12:312-21. 10.21037\/tlcr-23-83","journal-title":"Transl Lung Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez DR","year":"2016","unstructured":"Gomez DR, Blumenschein GR Jr, Lee JJ, et al.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016, 17:1672-82. 10.1016\/S1470-2045(16)30532-0","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez DR","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, et al.. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019, 37:1558-65. 10.1200\/JCO.19.00201","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12519","article-title":"A rare case of long-term survival from metachronous bilateral adrenal metastasis of lung adenocarcinoma after combined surgical removal and immunochemotherapy","volume":"5","author":"Tomiyama N","year":"2022","unstructured":"Tomiyama N, Naiki T, Naiki-Ito A, et al.. A rare case of long-term survival from metachronous bilateral adrenal metastasis of lung adenocarcinoma after combined surgical removal and immunochemotherapy. IJU Case Rep. 2022, 5:474-8. 10.1002\/iju5.12519","journal-title":"IJU Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15021","article-title":"Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer","volume":"14","author":"Lei SY","year":"2023","unstructured":"Lei SY, Xu HY, Li HS, et al.. Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2023, 14:2327-37. 10.1111\/1759-7714.15021","journal-title":"Thorac Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06945-7","article-title":"PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway","volume":"15","author":"Li N","year":"2024","unstructured":"Li N, Zuo R, He Y, et al.. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway. Cell Death Dis. 2024, 15:555. 10.1038\/s41419-024-06945-7","journal-title":"Cell Death Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2362","article-title":"Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Kozower BD","year":"2013","unstructured":"Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013, 143:e369S-99S. 10.1378\/chest.12-2362","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar P","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, et al.. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018, 4:e173501. 10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2004.09.020","article-title":"Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer","volume":"130","author":"Mercier O","year":"2005","unstructured":"Mercier O, Fadel E, de Perrot M, Mussot S, Stella F, Chapelier A, Dartevelle P. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005, 130:136-40. 10.1016\/j.jtcvs.2004.09.020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee CK","year":"2018","unstructured":"Lee CK, Man J, Lord S, et al.. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:210-6. 10.1001\/jamaoncol.2017.4427","journal-title":"JAMA Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok T","year":"2024","unstructured":"Mok T, Nakagawa K, Park K, et al.. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722. J Clin Oncol. 2024, 42:1252-64. 10.1200\/JCO.23.01017","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang JC","year":"2024","unstructured":"Yang JC, Lee DH, Lee JS, et al.. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol. 2024, 42:4029-39. 10.1200\/JCO.23.02747","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.041","article-title":"Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial","volume":"105","author":"Olson R","year":"2019","unstructured":"Olson R, Senan S, Harrow S, et al.. Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial. Int J Radiat Oncol Biol Phys. 2019, 105:943-7. 10.1016\/j.ijrobp.2019.08.041","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-025-02120-5","article-title":"Impact of metastasectomy on survival in patients with oligometastatic stage 4a lung cancer: a retrospective analysis","volume":"77","author":"Ulusan A","year":"2025","unstructured":"Ulusan A, Elma B, Danaci HZ, Sanli M, Isik AF. Impact of metastasectomy on survival in patients with oligometastatic stage 4a lung cancer: a retrospective analysis. Updates Surg. 2025, 77:937-45. 10.1007\/s13304-025-02120-5","journal-title":"Updates Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1322","article-title":"Outcomes of surgical treatment for isolated adrenal metastasis from non-small cell lung cancer","volume":"15","author":"Buero A","year":"2021","unstructured":"Buero A, Nardi WS, Chimondeguy DJ, Pankl LG, Lyons GA, Arboit DG, Quildrian SD. Outcomes of surgical treatment for isolated adrenal metastasis from non-small cell lung cancer. Ecancermedicalscience. 2021, 15:1322. 10.3332\/ecancer.2021.1322","journal-title":"Ecancermedicalscience"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-20679-2","article-title":"Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression","volume":"15","author":"Xie W","year":"2025","unstructured":"Xie W, Yan M, Wen F, et al.. Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression. Sci Rep. 2025, 15:36765. 10.1038\/s41598-025-20679-2","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462769-long-term-survival-achieved-by-combined-surgical-resection-and-immunotherapy-for-recurrent-adrenal-oligometastasis-of-lung-adenocarcinoma-a-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:18:38Z","timestamp":1773123518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462769-long-term-survival-achieved-by-combined-surgical-resection-and-immunotherapy-for-recurrent-adrenal-oligometastasis-of-lung-adenocarcinoma-a-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.104958","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}